Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Sam Chen

Associate

Nan Chen

Principal

Anna French

Partner

Jinda Gao

Executive Director

William Hu

Managing Partner

Duane Kuang

Co-Founder & Managing Partner

Grace Lee

Partner

Nisa Leung

Managing Partner

Shuo Mao

vice_president

Mark McDade

Partner

Gary Rieschel

Co-Founder & Managing Partner

Amy Tang

Venture Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Jing Wu

Partner

Kuantai Yeh

Partner

Janet Yu Ph.D

Partner

Alex Zhou

Partner

Past deals in Health Diagnostics

Soda Health

Series A in 2022
Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America.

CureGenetics

Series B in 2022
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Shanzhen

Series D in 2021
ShanZhen provides access to affordable regular health checkups, as well as personalized health management plans and insurance.

Lingyi Zhihui

Series B in 2021
Zuoshouyisheng's AI ​​doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.

Soda Health

Seed Round in 2021
Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America.

Berry Oncology

Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

LetsGetChecked

Series D in 2021
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Health Biotech

Series B in 2021
Beijing Health Biotech Co. Ltd. develops diagnostic and therapeutic products for diagnosis, treatment, and monitoring of Alzheimer's disease. The company offers diagnostic and therapeutic products, such as vitamins detection, Alzheimer's disease detection and treatment, prostate AA detection, ceramides test, therapeutic drug monitoring, and screening of neonatal genetic metabolic diseases for Alzheimer's disease, cardiovascular disease, urinary disease, genetic metabolic disease, therapeutic drug monitoring, metabolite detection, steroid hormone detection, trace element quantitative detection, vitamin family detection, and microbiological identification. It also offers clinical testing and research services. The company was founded in 2016 and is based in Beijing, China.

Hope Medicine

Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

ET Healthcare

Series G in 2021
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

New Horizon Health

Series E in 2020
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

New Horizon Health

Series D in 2020
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

Bioscience

Venture Round in 2020
Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.

CureGenetics

Series A in 2020
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Berry Oncology

Series A in 2020
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

Shanzhen

Series D in 2019
ShanZhen provides access to affordable regular health checkups, as well as personalized health management plans and insurance.

MyHealthTeams

Series B in 2019
MyHealthTeams is a San Francisco-based company building deeply engaging social networks for people living chronic conditions. MyHealthTeams is leading the way in patient engagement, making it easy for consumers to find and connect with others who understand what they face daily because they have been in their shoes. Eric Peacock & Mary Ray co-founded MyHealthTeams in 2012. As of 2019, MyHealthTeams has built and operates over 30 social networks to serve 90% of the addressable chronic condition population in 13 countries.

Bondent Technology

Series D in 2019
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

ZD Medical

Series A in 2019
ZD Medical is a medical device company manufacturing optical coherence tomography angiography devices.

LetsGetChecked

Series B in 2019
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

ET Healthcare

Series C in 2018
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

CureGenetics

Series A in 2018
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

ZD Medical

Series A in 2018
ZD Medical is a medical device company manufacturing optical coherence tomography angiography devices.

Bondent Technology

Series C in 2018
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

LetsGetChecked

Series A in 2018
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Berry Oncology

Series A in 2018
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

Bioscience

Series C in 2017
Bioscience integrates R&D, manufacture, marketing and provides related technical supports for IVD instruments and reagents.

New Horizon Health

Series B in 2017
New Horizon Health, founded in 2015 and headquartered in Hangzhou, China, specializes in developing advanced technologies for the detection and screening of gastrointestinal cancers, particularly gastric and colorectal cancers. The company offers innovative products based on fecal gene analysis (FIT-DNA) technology, enabling users to conduct at-home tests that identify signs of colon cancer and significant adenomas. This technology facilitates earlier detection of precancerous lesions compared to conventional blood tests. By leveraging big data and artificial intelligence, New Horizon Health enhances its cancer screening solutions, aiming to improve public health outcomes. The company also emphasizes its commitment to making early cancer screening accessible to households, thereby striving to reduce the incidence and mortality associated with cancer.

MyHealthTeams

Series A in 2017
MyHealthTeams is a San Francisco-based company building deeply engaging social networks for people living chronic conditions. MyHealthTeams is leading the way in patient engagement, making it easy for consumers to find and connect with others who understand what they face daily because they have been in their shoes. Eric Peacock & Mary Ray co-founded MyHealthTeams in 2012. As of 2019, MyHealthTeams has built and operates over 30 social networks to serve 90% of the addressable chronic condition population in 13 countries.

ET Healthcare

Venture Round in 2017
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

Bondent Technology

Series B in 2017
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

Diandoc

Seed Round in 2017
Diandoc is a surgical referral service platform.

Bondent Technology

Series C in 2016
Provider of integrated oral medical solutions for oral health and dental industry. The company offers technical training, operation and management consulting services to their clients. The company also involves in the design, development, manufacturing, and sales of oral medical equipment, providing a full fledged ecosystem for the dental and oral health industry.

CMLabs

Series B in 2016
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

JHT TCM Clinics

Series B in 2016
JHT TCM Clinics

ET Healthcare

Series B in 2015
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various medical settings, including hospitals and clinics. The company has developed the Pylon Immunochemistry System, an integrated turnkey solution that addresses the immunodiagnostics needs across several areas, such as inflammation, cardiac function, fertility, infectious diseases, and tumors. Additionally, the Pylon BNP Immunoassay aids in managing heart failure by measuring B-type natriuretic peptide levels in plasma. ET Healthcare’s offerings include a variety of immunoassays for cardiac markers, blood clots, and other health conditions, facilitating simplified blood analysis for physicians. Based in Palo Alto, California, the company also has offices in Shanghai, China, and operates manufacturing facilities in Suzhou, China.

CMLabs

Series A in 2015
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

Amoy Diagnostics

Series B in 2015
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.

WeDoctor

Venture Round in 2014
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical and health technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing solutions that utilize medical cloud and artificial intelligence technologies for various stakeholders, including governments, hospitals, and primary medical institutions. WeDoctor offers a range of services through its WeDoctor Cloud platform, which facilitates online and offline medical services, general practice, specialty consultations, and appointment registrations. Additionally, the company provides managed health services through WeDoctor HMO, aiming to enhance the medical care experience for users. With a mission to improve access to healthcare and promote overall wellness, WeDoctor strives to empower individuals and families through innovative healthcare solutions that integrate both digital and traditional services.
Beijing Richen-Force Science & Technology Co., Ltd., founded in July 2002, specializes in the development, manufacture, and marketing of medical devices, particularly in the field of gastroenterology. The company offers a range of products, including 13C urea breath diagnosis systems and test kits, Mirocam capsules, heat probe treatment systems for gastric diseases, and HpSA immune cards. It has established R&D centers and production bases in Beijing, Guangzhou, and Taizhou, as well as subsidiaries in Italy and Brazil, and a research center in the USA. Richen-Force has achieved significant global reach, exporting its 13C-UBT products to over 60 countries and serving more than 6,000 customers. The 13C urea breath test, known for its non-invasive and painless nature, has become the preferred standard for H. Pylori diagnosis, holding a 70% market share in China and positioning the company as a leading competitor in the global market for this technology.

Amoy Diagnostics

Series B in 2013
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.

JHT TCM Clinics

Series A in 2013
JHT TCM Clinics
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. It offers tumor markers, human papilloma virus test kits, ToRCH products, Y chromosome microdeletions test kits, and multiplex immunoassay systems. The company was founded in 2003 and is based in Shanghai, China.
Goodwill Infotech provides clinical information.